Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=title
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=title", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=title", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=title", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=title" }, "data": [ { "type": "Grant", "id": "9372", "attributes": { "award_id": "3UL1TR001857-05S3", "title": "University of Pittsburgh Clinical and Translational Science Institute", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 21695, "first_name": "Christopher", "last_name": "Hartshorn", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-11-01", "end_date": "2021-07-31", "award_amount": 976487, "principal_investigator": { "id": 23202, "first_name": "STEVEN E", "last_name": "REIS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating effect on the physical, social, and economic health of communities throughout the world. To evaluate the sero-prevalence of immunity against SARS-COV-2 in the United States, this scientific partnership of Clinical and Translational Science Awardees (CTSAs) at academic medical centers (University of Alabama and University of Pittsburgh) and the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Disease identified, enrolled, and obtained blood samples from 11,300 adults who have not been diagnosed with COVID-19 representing almost every county in the US and all major racial and ethnic groups. We will now seek consent from these participants to provide follow-up data and blood samples and 6 and 12 months after enrollment (Aim 1) and determine the immune attributes associated with health outcomes (Aim 2), including for those in underrepresented populations and across the life course. This collaborative partnership of the intramural NIAID program and extramurally funded CTSA Hubs will efficiently survey, obtain blood samples from, and determine changes in the prevalence of SARS-CoV-2 antibodies in a large, heterogeneous cohort of adults without known clinical COVID-19 disease. Knowledge gained from this seroprevalence study will advance our understanding of SARS-CoV-2 humoral immunity at the population level and inform population strategies for vaccination – both for the COVID-19 pandemic and future epidemics involving novel pathogens.", "keywords": [ "2019-nCoV", "Academic Medical Centers", "Adult", "Alabama", "Antibodies", "Antibody titer measurement", "Back", "Biological Assay", "Biological Markers", "Blood specimen", "COVID-19", "COVID-19 detection", "COVID-19 diagnosis", "COVID-19 outbreak", "COVID-19 pandemic", "Clinical", "Clinical Sciences", "Communicable Diseases", "Community Health", "Consent", "County", "Data", "Development", "Diagnostic Reagent Kits", "Disease", "Economics", "Enrollment", "Enzyme-Linked Immunosorbent Assay", "Epidemic", "Ethnic group", "Extramural Activities", "Funding", "Future", "General Population", "Geography", "Health", "Herd Immunity", "Home", "Humoral Immunities", "Immune", "Immune response", "Immunity", "Immunoglobulin G", "Immunoglobulin M", "Individual", "Infection", "Infectious Diseases Research", "Institutes", "Knowledge", "Life Cycle Stages", "Longevity", "Measures", "Monitor", "Morbidity - disease rate", "National Institute of Allergy and Infectious Disease", "Natural History", "Outcome", "Participant", "Phase", "Population", "Prevalence", "Race", "Recontacts", "SARS-CoV-2 antibody", "SARS-CoV-2 immunity", "SARS-CoV-2 spike protein", "Sampling", "Seroprevalences", "Serum", "Special Population", "Surveys", "Testing", "Translational Research", "Underrepresented Populations", "United States", "Universities", "Viral", "Virus", "antibody detection", "antibody test", "clinical center", "cohort", "emerging pathogen", "follow-up", "health economics", "insight", "mortality", "novel", "novel virus", "pandemic disease", "pathogen", "programs", "response", "screening", "social", "vaccination strategy" ], "approved": true } }, { "type": "Grant", "id": "9074", "attributes": { "award_id": "3UM1AI069511-14S1", "title": "University of Rochester HIV/AIDS Clinical Trials Unit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 24868, "first_name": "Teri L.", "last_name": "Greenfield", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-06-04", "end_date": "2020-11-30", "award_amount": 290519, "principal_investigator": { "id": 24876, "first_name": "MICHAEL C", "last_name": "KEEFER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 464, "ror": "https://ror.org/022kthw22", "name": "University of Rochester", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 464, "ror": "https://ror.org/022kthw22", "name": "University of Rochester", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The University of Rochester (UR) Clinical Microbiology laboratory is a CLIA-certified laboratory that offers bacteriology (ID and susceptibility), immunology, mycobacteriology, mycology, parasitology, serology, TB and virology testing including specialized antibiotic and antifungal studies. The laboratory evaluates and adds infectious diseases molecular diagnostic tests on an ongoing basis and has sufficient capability for SARS-CoV-2 RNA testing to meet current clinical demands.", "keywords": [ "2019-nCoV", "3-Dimensional", "AIDS/HIV problem", "Antibiotics", "Antifungal Agents", "Bacteriology", "CLIA certified", "Clinical", "Clinical Microbiology", "Clinical Trials Unit", "Communicable Diseases", "Immunology", "Infection", "Laboratories", "Medical", "Molecular Diagnostic Testing", "Parasitology", "Patients", "Predisposition", "RNA", "Sampling", "Serologic tests", "System", "Testing", "The science of Mycology", "Time", "Universities", "virology" ], "approved": true } }, { "type": "Grant", "id": "6478", "attributes": { "award_id": "3UM1AI148450-01S1", "title": "University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21742, "first_name": "Marina", "last_name": "Lee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-03-24", "end_date": "2022-11-30", "award_amount": 270156, "principal_investigator": { "id": 21743, "first_name": "Angela Ramona", "last_name": "Branche", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 21744, "first_name": "Ann R", "last_name": "Falsey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 464, "ror": "https://ror.org/022kthw22", "name": "University of Rochester", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The Vaccine and Treatment Evaluation Units (VTEUs) are a critical resource for the NIAID Infectious Diseases Clinical Research Consortium to conduct clinical research and trials to evaluate vaccines, preventive biologics, therapeutics, diagnostics, predictive markers, and devices for the treatment and prevention of infectious diseases in people of all ages and risk categories. The VTEU network sites must flexible and respond to emerging threats and changing NIAID priorities. To this end, the University of Rochester VTEU (UR VTEU) will collaborate with NIAID and the VTEU leadership group (VTEU LG) to address and prioritize initiatives for infectious diseases such as respiratory, enteric, sexually transmitted infections and antibiotic resistant organisms as well as maintain flexibility to switch focus to emerging threats as the need arises. The University of Rochester is fortunate to enjoy a community with a very positive attitude towards clinical research and collaborative relationships between the major healthcare providers in the city providing access to all the hospitals, clinics and practices in the area. The UR VTEU offers a very experienced administrative and clinical group with a proven track record of successful multicenter clinical trial work. With the support of the VTEU LG, the UR VTEU will be well positioned to develop as well as implement concepts and projects that address important NIAID priorities and formulate best practices, efficiencies and standard operating procedures among VTEU sites. UR VTEU investigators have expertise in adult and pediatric clinical research as well as recruitment of vulnerable populations into clinical trials and thus can anticipate successful recruitment of young and older adults, infants, young children and adolescents, and pregnant women. Additionally, the close relationship of the Monroe County Health Department with the University provides access to patients with sexually transmitted diseases for study participation. We will provide capacity to perform phase 1-3 clinical trials and pharmacokinetic studies as well as surge capacity in terms of personnel and clinical research sites to rapidly respond to urgent NIAID demands. Importantly, our investigators have experience conducting challenge and isolation studies and can provide VTEU facilities for such projects. Our research laboratory expertise will provide the VTEU network with a variety of state of the art technologies to interrogate the host response to infection and immunization as well as develop a deeper understanding of pathogenesis for many infectious diseases. Specifically, core faculty have expertise in a wide range of novel immunologic assays as well as transcriptional and microbiome analysis. In addition, the UR VTEU will provide research opportunities and education for junior faculty to train the next generation of physician scientists. All clinical trials will adhere to NIAID/NIH requirements and comply with Good Clinical Practice. In summary, the UR VTEU site will offer an enthusiastic and diverse group of investigators with a track record of participating in collaborative research and the necessary scientific, clinical, administrative and organizational structure to support NIAID activities.", "keywords": [ "Address", "Adult", "Age", "Antibiotic-resistant organism", "Antibiotics", "Area", "Biological Response Modifier Therapy", "Categories", "Child", "Childhood", "Cities", "Clinic", "Clinical", "Clinical Research", "Clinical Trials", "Communicable Diseases", "Communities", "County", "Data", "Data Analyses", "Development", "Devices", "Diagnostic", "Disease", "Disease Outbreaks", "Drug Kinetics", "Education", "Elderly", "Enrollment", "Ensure", "Enteral", "Evaluation", "Faculty", "Genetic Transcription", "Good Clinical Practice", "Happiness", "Health", "Health Personnel", "Hospitals", "Human Resources", "Immune response", "Immunization", "Immunology procedure", "Infant", "Infection", "Influenza", "Intervention", "Investigation", "Laboratories", "Laboratory Research", "Leadership", "Malaria", "Measles", "Methods", "Multi-Drug Resistance", "Multi-Institutional Clinical Trial", "Multicenter Trials", "Mumps", "National Institute of Allergy and Infectious Disease", "Pathogenesis", "Patients", "Pertussis", "Pharmacy facility", "Phase", "Physicians", "Policies", "Poliomyelitis", "Positioning Attribute", "Pregnant Women", "Preparation", "Prevention", "Preventive", "Procedures", "Protocols documentation", "Reporting", "Research", "Research Personnel", "Resources", "Risk", "Sampling", "Scientist", "Secure", "Sexually Transmitted Diseases", "Site", "Surgeon", "Target Populations", "Technology", "Testing", "Therapeutic", "Time", "Training", "Tuberculosis", "United States", "United States National Institutes of Health", "Universities", "Vaccination", "Vaccines", "Virus", "Vulnerable Populations", "War", "Work", "clinical research site", "combat", "data management", "design", "drug resistant bacteria", "experience", "fight against", "flexibility", "improved", "innovation", "microbiome analysis", "next generation", "novel", "novel therapeutics", "novel vaccines", "organizational structure", "pathogen", "pre-clinical research", "predictive marker", "premature", "preservation", "recruit", "respiratory", "vaccine evaluation", "young adult", "young woman" ], "approved": true } }, { "type": "Grant", "id": "5661", "attributes": { "award_id": "3UM1AI148450-02S1", "title": "University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19568, "first_name": "Marina", "last_name": "Lee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-03-24", "end_date": "2021-11-30", "award_amount": 244250, "principal_investigator": { "id": 19569, "first_name": "Angela Ramona", "last_name": "Branche", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 19570, "first_name": "Ann R", "last_name": "Falsey", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 464, "ror": "https://ror.org/022kthw22", "name": "University of Rochester", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The Vaccine and Treatment Evaluation Units (VTEUs) are a critical resource for the NIAID Infectious Diseases Clinical Research Consortium to conduct clinical research and trials to evaluate vaccines, preventive biologics, therapeutics, diagnostics, predictive markers, and devices for the treatment and prevention of infectious diseases in people of all ages and risk categories. The VTEU network sites must flexible and respond to emerging threats and changing NIAID priorities. To this end, the University of Rochester VTEU (UR VTEU) will collaborate with NIAID and the VTEU leadership group (VTEU LG) to address and prioritize initiatives for infectious diseases such as respiratory, enteric, sexually transmitted infections and antibiotic resistant organisms as well as maintain flexibility to switch focus to emerging threats as the need arises. The University of Rochester is fortunate to enjoy a community with a very positive attitude towards clinical research and collaborative relationships between the major healthcare providers in the city providing access to all the hospitals, clinics and practices in the area. The UR VTEU offers a very experienced administrative and clinical group with a proven track record of successful multicenter clinical trial work. With the support of the VTEU LG, the UR VTEU will be well positioned to develop as well as implement concepts and projects that address important NIAID priorities and formulate best practices, efficiencies and standard operating procedures among VTEU sites. UR VTEU investigators have expertise in adult and pediatric clinical research as well as recruitment of vulnerable populations into clinical trials and thus can anticipate successful recruitment of young and older adults, infants, young children and adolescents, and pregnant women. Additionally, the close relationship of the Monroe County Health Department with the University provides access to patients with sexually transmitted diseases for study participation. We will provide capacity to perform phase 1-3 clinical trials and pharmacokinetic studies as well as surge capacity in terms of personnel and clinical research sites to rapidly respond to urgent NIAID demands. Importantly, our investigators have experience conducting challenge and isolation studies and can provide VTEU facilities for such projects. Our research laboratory expertise will provide the VTEU network with a variety of state of the art technologies to interrogate the host response to infection and immunization as well as develop a deeper understanding of pathogenesis for many infectious diseases. Specifically, core faculty have expertise in a wide range of novel immunologic assays as well as transcriptional and microbiome analysis. In addition, the UR VTEU will provide research opportunities and education for junior faculty to train the next generation of physician scientists. All clinical trials will adhere to NIAID/NIH requirements and comply with Good Clinical Practice. In summary, the UR VTEU site will offer an enthusiastic and diverse group of investigators with a track record of participating in collaborative research and the necessary scientific, clinical, administrative and organizational structure to support NIAID activities.", "keywords": [ "Address", "Adult", "Age", "Antibiotic-resistant organism", "Antibiotics", "Area", "Biological Response Modifier Therapy", "Categories", "Child", "Childhood", "Cities", "Clinic", "Clinical", "Clinical Research", "Clinical Trials", "Communicable Diseases", "Communities", "County", "Data", "Data Analyses", "Development", "Devices", "Diagnostic", "Disease", "Disease Outbreaks", "Drug Kinetics", "Education", "Elderly", "Enrollment", "Ensure", "Enteral", "Evaluation", "Faculty", "Genetic Transcription", "Good Clinical Practice", "Happiness", "Health", "Health Personnel", "Hospitals", "Human Resources", "Immune response", "Immunization", "Immunology procedure", "Infant", "Infection", "Influenza", "Intervention", "Investigation", "Laboratories", "Laboratory Research", "Leadership", "Malaria", "Measles", "Methods", "Multi-Drug Resistance", "Multi-Institutional Clinical Trial", "Multicenter Trials", "Mumps", "National Institute of Allergy and Infectious Disease", "Pathogenesis", "Patients", "Pertussis", "Pharmacy facility", "Phase", "Physicians", "Policies", "Poliomyelitis", "Positioning Attribute", "Pregnant Women", "Preparation", "Prevention", "Preventive", "Procedures", "Protocols documentation", "Reporting", "Research", "Research Personnel", "Resources", "Risk", "Sampling", "Scientist", "Secure", "Sexually Transmitted Diseases", "Site", "Surgeon", "Target Populations", "Technology", "Testing", "Therapeutic", "Time", "Training", "Tuberculosis", "United States", "United States National Institutes of Health", "Universities", "Vaccination", "Vaccines", "Virus", "Vulnerable Populations", "War", "Work", "clinical research site", "combat", "data management", "design", "drug resistant bacteria", "experience", "fight against", "flexibility", "improved", "innovation", "microbiome analysis", "next generation", "novel", "novel therapeutics", "novel vaccines", "organizational structure", "pathogen", "pre-clinical research", "predictive marker", "premature", "preservation", "recruit", "respiratory", "vaccine access", "vaccine evaluation", "young adult", "young woman" ], "approved": true } }, { "type": "Grant", "id": "845", "attributes": { "award_id": "2118276", "title": "University of Washington - School of Oceanography for R/V Thomas G. Thompson and R/V Rachel Carson Shipboard Scientific Support Equipment (SSSE)", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Geosciences (GEO)" ], "program_reference_codes": [], "program_officials": [ { "id": 2019, "first_name": "James", "last_name": "Holik", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-03-15", "end_date": "2023-02-28", "award_amount": 97154, "principal_investigator": { "id": 2020, "first_name": "Robert", "last_name": "Kamphaus", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Requests are made by the University of Washington for Shipboard Scientific Support Equipment (SSSE) on R/V Thompson, a 274-foot general purpose, global class research vessel, and R/V Rachael Carson, a newly outfitted 72-foot coastal research vessel, both operated as part of the US Academic Research Fleet (ARF). In 2020, Thompson, in a COVID-shortened season, completed 202 funded days with 131 (65%) of them for NSF. For 2021, the vessel is scheduled for 277 total days with 224 (80%) days for NSF. Carson had 41 days in 2020 with 1 NSF day. For 2021, there are 71 days scheduled, 32 (45%) of which are for NSF.With this proposal, UW provides technical descriptions and rationale for the acquisition of the following Shipboard Scientific Support Equipment:Purchase and Install Boat Davit on R/V Rachel Carson\t$51,807Design and Install ADCP Well in Hull of R/V Rachel Carson\t$26,630Purchase Wide Throat Metered Block for R/V Rachel Carson\t$18,717Replace starboard aft main deck crane on R/V Thompson\t$252,500\t\t\t\t\t\t$349,654Broader ImpactsThe principal impact of the present proposal is under Merit Review Criterion 2 of the Proposal Guidelines (NSF 13-589). It provides infrastructure support for scientists to use the vessel and its shared-use instrumentation in support of their NSF-funded oceanographic research projects (which individually undergo separate review by the relevant research program of NSF). The acquisition, maintenance and operation of shared-use instrumentation allows NSF-funded researchers from any US university or lab access to working, calibrated instruments for their research, reducing the cost of that research, and expanding the base of potential researchers.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "6158", "attributes": { "award_id": "3U01AI151698-02S1", "title": "University of Washington Arboviral Research Network (UWARN)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 20909, "first_name": "SARA ELAINE", "last_name": "Woodson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-22", "end_date": "2025-04-30", "award_amount": 176500, "principal_investigator": { "id": 20910, "first_name": "Michael J", "last_name": "Gale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 20911, "first_name": "PETER MACGARR", "last_name": "RABINOWITZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 20912, "first_name": "WESLEY C", "last_name": "VAN VOORHIS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 20913, "first_name": "JUDITH N.", "last_name": "WASSERHEIT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract: The United World Antiviral Research Network (UWARN, formerly referred to as the University of Washington Arboviral Research Network) will address emerging and re-emerging infectious diseases by carrying out research on arboviruses that include current high burden pathogens including dengue, chikungunya, and Zika viruses. Arboviruses also include emerging and re-emerging viruses such as Mayaro, Una, Usutu, Japanese encephalitis, yellow fever, Crimean-Congo hemorrhagic fever, and Oropouche viruses. UWARN will leverage the UW Alliance (formerly Metacenter) for Pandemic Disease Preparedness and strong research laboratory partners in Brazil, Senegal, South Africa, Pakistan and Taiwan as well as the UW Department of Global Health global reach in capacity building. The UWARN international Collaborating Partners have institution-based and population-based cohorts in place to carry out the planned research and monitor for new virus emergence. The proposed UWARN research will create new human viral-neutralizing monoclonal antibodies (Hu-nMabs) that can be used as therapeutics or diagnostics. UWARN research will also create new diagnostics, created ab initio by the Institute for Protein Design, as artificial proteins that release light when antibodies to virus are present in body fluids. Finally, UWARN research will generate an understanding of how viruses manipulate the human innate immune system, and this information will be used to design biomarkers to predict severe disease as well as to suggest host-directed therapies that could lead to better outcomes after arboviral infection. The proposed technologies are generic and could be rapidly adapted to any future emerging arbovirus threat. UWARN collaborators span virology, bacteriology, mycology, and parasitic infections, such that UWARN can respond to diverse emerging infectious diseases threats. UWARN international laboratories have advanced capabilities including biorepositories with generator-power backed-up -80C freezers, next-generation sequencing (NGS) capabilities, fluorescence cell sorting, and BSL-3 containment facilities. UWARN cohorts have biobanked samples taken from individuals during acute febrile illnesses, with known and unknown arboviral diseases, and partnership sites are poised for prospective collection of population and facility–based samples. UWARN labs will use metagenomic NGS to detect novel viral emergence in affiliated cohorts. UWARN Partners have collaborating entomologists and veterinarians to sample arthropod vectors and animal reservoirs as needed. Additional innovative capacity included the Brazil UWARN partner’s mobile van with on board NGS capability for real-time, on-site viral sequencing and sampling to viral identification in less than 18 hrs. A second partner, IRESSEF in Senegal, plans to set up a similar mobile vehicle for viral sampling and sequencing in Senegal and the Brazil group will collaborate with IRESSEF on technology transfer and best practices. UWARN partners will serve as a resource to other Emerging Infectious Diseases Research Centers (EIDRC) providing expertise in monoclonal antibodies, protein design, and host directed therapies.", "keywords": [ "Acute", "Address", "Administrative Coordination", "Alphavirus", "Animals", "Antibodies", "Antiviral Agents", "Arbovirus Infections", "Arboviruses", "Area", "Arthropod Vectors", "Back", "Bacteriology", "Binding", "Biological Assay", "Biological Markers", "Blood", "Body Fluids", "Brazil", "Cell Separation", "Chikungunya virus", "Clinical", "Clinical Management", "Clinical Trials", "Collaborations", "Collection", "Congo", "Containment", "Data", "Dengue", "Dengue Infection", "Dengue Virus", "Detection", "Development", "Diagnosis", "Diagnostic", "Diagnostic Reagent", "Disease", "Emergency Situation", "Emerging Communicable Diseases", "Engineering", "Enzyme-Linked Immunosorbent Assay", "Epitopes", "Far East", "Fever", "Flavivirus", "Fluorescence", "Freezing", "Future", "Genomic approach", "Human", "Immune response", "Immune system", "Immunoglobulin G", "Individual", "Infection", "Infectious Diseases Research", "Innate Immune Response", "Innate Immune System", "Institutes", "Institution", "International", "Intervention", "Investigation", "Japanese Encephalitis", "Knowledge", "Laboratories", "Laboratory Research", "Lead", "Light", "Logistics", "Measurement", "Metagenomics", "Microcephaly", "Molecular", "Monitor", "Monoclonal Antibodies", "Natural Immunity", "Oropouche virus", "Orthobunyavirus", "Outcome", "Pakistan", "Parasitic infection", "Pathogenesis", "Pathway interactions", "Patients", "Population", "Prevalence", "Process", "Production", "Protein Engineering", "Proteins", "Readiness", "Reagent", "Research", "Resources", "Rift Valley Fever", "Risk", "Sampling", "Senegal", "Sensitivity and Specificity", "Serology", "Seroprevalences", "Site", "South Africa", "South America", "Specimen", "Statistical Data Interpretation", "Structure", "System", "Taiwan", "Technology", "Technology Transfer", "Testing", "The science of Mycology", "Therapeutic", "Time", "Universities", "Vaccines", "Variant", "Veterinarians", "Viral", "Viral Antibodies", "Viral Hemorrhagic Fevers", "Viral Load result", "Virus", "Virus Diseases", "Washington", "Yellow Fever", "ZIKA", "Zika Virus", "arthropod-borne", "base", "biobank", "candidate marker", "chikungunya", "cohort", "cross reactivity", "data management", "design", "experience", "global health", "global health emergency", "human monoclonal antibodies", "improved", "improved outcome", "innovation", "neutralizing antibody", "neutralizing monoclonal antibodies", "next generation sequencing" ], "approved": true } }, { "type": "Grant", "id": "7558", "attributes": { "award_id": "3U01AI151698-01S1", "title": "University of Washington Arboviral Research Network (UWARN)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 20939, "first_name": "Jean Lois", "last_name": "Patterson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-05-22", "end_date": "2022-04-30", "award_amount": 121420, "principal_investigator": { "id": 10006, "first_name": "Michael J", "last_name": "Gale", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 20911, "first_name": "PETER MACGARR", "last_name": "RABINOWITZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 20912, "first_name": "WESLEY C", "last_name": "VAN VOORHIS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 20913, "first_name": "JUDITH N.", "last_name": "WASSERHEIT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Abstract: The United World Antiviral Research Network (UWARN, formerly referred to as the University of Washington Arboviral Research Network) will address emerging and re-emerging infectious diseases by carrying out research on arboviruses that include current high burden pathogens including dengue, chikungunya, and Zika viruses. Arboviruses also include emerging and re-emerging viruses such as Mayaro, Una, Usutu, Japanese encephalitis, yellow fever, Crimean-Congo hemorrhagic fever, and Oropouche viruses. UWARN will leverage the UW Alliance (formerly Metacenter) for Pandemic Disease Preparedness and strong research laboratory partners in Brazil, Senegal, South Africa, Pakistan and Taiwan as well as the UW Department of Global Health global reach in capacity building. The UWARN international Collaborating Partners have institution-based and population-based cohorts in place to carry out the planned research and monitor for new virus emergence. The proposed UWARN research will create new human viral-neutralizing monoclonal antibodies (Hu-nMabs) that can be used as therapeutics or diagnostics. UWARN research will also create new diagnostics, created ab initio by the Institute for Protein Design, as artificial proteins that release light when antibodies to virus are present in body fluids. Finally, UWARN research will generate an understanding of how viruses manipulate the human innate immune system, and this information will be used to design biomarkers to predict severe disease as well as to suggest host-directed therapies that could lead to better outcomes after arboviral infection. The proposed technologies are generic and could be rapidly adapted to any future emerging arbovirus threat. UWARN collaborators span virology, bacteriology, mycology, and parasitic infections, such that UWARN can respond to diverse emerging infectious diseases threats. UWARN international laboratories have advanced capabilities including biorepositories with generator-power backed-up -80C freezers, next-generation sequencing (NGS) capabilities, fluorescence cell sorting, and BSL-3 containment facilities. UWARN cohorts have biobanked samples taken from individuals during acute febrile illnesses, with known and unknown arboviral diseases, and partnership sites are poised for prospective collection of population and facility–based samples. UWARN labs will use metagenomic NGS to detect novel viral emergence in affiliated cohorts. UWARN Partners have collaborating entomologists and veterinarians to sample arthropod vectors and animal reservoirs as needed. Additional innovative capacity included the Brazil UWARN partner’s mobile van with on board NGS capability for real-time, on-site viral sequencing and sampling to viral identification in less than 18 hrs. A second partner, IRESSEF in Senegal, plans to set up a similar mobile vehicle for viral sampling and sequencing in Senegal and the Brazil group will collaborate with IRESSEF on technology transfer and best practices. UWARN partners will serve as a resource to other Emerging Infectious Diseases Research Centers (EIDRC) providing expertise in monoclonal antibodies, protein design, and host directed therapies.", "keywords": [ "Acute", "Address", "Administrative Coordination", "Alphavirus", "Animals", "Antibodies", "Antiviral Agents", "Arbovirus Infections", "Arboviruses", "Area", "Arthropod Vectors", "Arthropods", "Back", "Bacteriology", "Binding", "Biological Assay", "Biological Markers", "Blood", "Body Fluids", "Brazil", "Bunyaviridae", "Cell Separation", "Chikungunya virus", "Clinical", "Clinical Management", "Clinical Trials", "Collaborations", "Collection", "Congo", "Containment", "Data", "Dengue", "Dengue Infection", "Dengue Virus", "Detection", "Development", "Diagnosis", "Diagnostic", "Diagnostic Reagent", "Disease", "Emergency Situation", "Emerging Communicable Diseases", "Engineering", "Enzyme-Linked Immunosorbent Assay", "Epitopes", "Far East", "Fever", "Flavivirus", "Fluorescence", "Freezing", "Future", "Genomic approach", "Human", "Immune response", "Immune system", "Immunoglobulin G", "Individual", "Infection", "Infectious Diseases Research", "Innate Immune Response", "Innate Immune System", "Institutes", "Institution", "International", "Intervention", "Investigation", "Japanese Encephalitis", "Knowledge", "Laboratories", "Laboratory Research", "Lead", "Light", "Logistics", "Measurement", "Metagenomics", "Microcephaly", "Molecular", "Monitor", "Monoclonal Antibodies", "Natural Immunity", "Oropouche virus", "Outcome", "Pakistan", "Parasitic infection", "Pathogenesis", "Pathway interactions", "Patients", "Population", "Prevalence", "Process", "Production", "Protein Engineering", "Proteins", "Readiness", "Reagent", "Research", "Resources", "Rift Valley Fever", "Risk", "Sampling", "Senegal", "Sensitivity and Specificity", "Serological", "Seroprevalences", "Site", "South Africa", "South America", "Specimen", "Statistical Data Interpretation", "Structure", "System", "Taiwan", "Technology", "Technology Transfer", "Testing", "The science of Mycology", "Therapeutic", "Time", "Universities", "Vaccines", "Variant", "Veterinarians", "Viral", "Viral Antibodies", "Viral Hemorrhagic Fevers", "Viral Load result", "Virus", "Virus Diseases", "Washington", "Yellow Fever", "ZIKA", "Zika Virus", "base", "biobank", "candidate marker", "chikungunya", "cohort", "cross reactivity", "data management", "design", "experience", "global health", "global health emergency", "human monoclonal antibodies", "improved", "improved outcome", "innovation", "neutralizing antibody", "neutralizing monoclonal antibodies", "next generation sequencing", "nove" ], "approved": true } }, { "type": "Grant", "id": "846", "attributes": { "award_id": "2114894", "title": "University of Washington for R/V Thomas G. Thompson and R/V Rachel Carson Oceanographic Instrumentation 2021", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Geosciences (GEO)" ], "program_reference_codes": [], "program_officials": [ { "id": 2021, "first_name": "James", "last_name": "Holik", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-04-01", "end_date": "2023-03-31", "award_amount": 43303, "principal_investigator": { "id": 2022, "first_name": "Robert", "last_name": "Kamphaus", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Requests are made by the University of Washington for Oceanographic Instrumentation (OI) on R/V Thompson, a 274-foot general purpose, global class research vessel, and R/V Rachael Carson, a newly outfitted 72-foot coastal research vessel, both operated as part of the US Academic Research Fleet (ARF). In 2020, Thompson, in a COVID-shortened season, completed 202 funded days with 131 (65%) of them for NSF. For 2021, the vessel is scheduled for 277 total days with 224 (80%) days for NSF. Carson had 41 days in 2020 with 1 NSF day. For 2021, there are 71 days scheduled, 32 (45%) of which are for NSF.With this proposal, UW provides technical descriptions and rationale for the acquisition of the following Oceanographic Instrumentation:Network Time Protocol (NTP) servers (2)\t$14,058\t-80C Chest Freezer\t$8,795\tNiskin A (Thompson and Carson)\t$20,450\tC-Nav 5000 Receiver\t$13,717\t\t\t\t\t\t\t$57,020\tBroader Impacts\t\t\t\t\tThe principal impact of the present proposal is under Merit Review Criterion 2 of the Proposal Guidelines (NSF 13-589). It provides infrastructure support for scientists to use the vessel and its shared-use instrumentation in support of their NSF-funded oceanographic research projects (which individually undergo separate review by the relevant research program of NSF). The acquisition, maintenance and operation of shared-use instrumentation allows NSF-funded researchers from any US university or lab access to working, calibrated instruments for their research, reducing the cost of that research, and expanding the base of potential researchers.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "14863", "attributes": { "award_id": "1T32GM153182-01", "title": "University of Washington Medical Scientist Training Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 31549, "first_name": "Andrea", "last_name": "Keane-Myers", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-01", "end_date": "2029-06-30", "award_amount": 1798078, "principal_investigator": { "id": 31550, "first_name": "MARSHALL S.", "last_name": "HORWITZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The University of Washington (UW) Medical Scientist Training Program (MSTP) was established in 1970 and is the only MD-PhD program in the five “WWAMI” states (Washington, Wyoming, Alaska, Montana, and Idaho) comprising a quarter of the landmass of the United States. Our program has thus far produced 285 graduates, 78% of whom have been employed in scientific research throughout their careers. Our goal is to leverage institutional and national resources to build an educational pipeline leading to the development and identification of a diverse group of talented trainees and equip them with the skills, mentorship, role models, and motivation required to advance the frontiers of biomedical science and technology. Among multiple accomplishments, students and graduates of our program created the Apple Macintosh computer and one of the first enzyme replacement therapies for metabolic disease, have provided fundamental insights into the nature of stem cells, the sequence and structure of the human genome, and the infectivity of SARS-CoV-2, and have led similarly successful MD-PhD programs elsewhere, thereby exponentially amplifying our program’s impact on training the next generation of physician-scientists. Our competitive program has grown to an annual class of 15, comprising approximately one-fifth of all medical students in Seattle. For each offer of admission, we receive over 23 training- grant-eligible applications. Of our 96 current trainees, 21% are from populations under-represented in medicine and 19% are from disadvantaged backgrounds. Our partnership with Morehouse School of Medicine enriches both institutions. Our trainees carry out their PhD research with UW faculty mentors at the UW, Fred Hutchinson Cancer Research Center (Hutch), Seattle Children's Hospital Research Institute, and Benaroya Research Institute. Current trainees' PhD departments and programs include Molecular and Cellular Biology, Neuroscience, Genome Sciences, Bioengineering, Computer Science, Molecular Engineering, Chemistry, and Epidemiology. They are mentored by a highly trained group of 81 well-funded, diverse, and gender-balanced distinguished faculty drawn from across ranks of junior to senior investigators, who emphasize and practice responsible, reproducible science in safe training environments. Our program integrates medical and graduate education, while reducing redundancy. Mean time to completion is 8.3 years and on a shortening trajectory, with minimal attrition of 2.6%. Over half of trainees receive NIH F30 independent fellowships. Over the last 15 years, graduates published a mean of 6.7 peer-reviewed papers, including 2.8 as first-authors, many of which are exceptionally impactful and have altered the course of research in their fields. Nearly all graduates go on to research-related residencies at leading institutions, predominantly in fields conducive to long-term retention in research. We continually evaluate our outcomes, measure our progress toward its overarching objective of producing resilient physician-scientists pushing the envelope at the interface of science and medicine, and iteratively evolve our program to stay at the forefront of evidence-based innovations in training practices.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "7572", "attributes": { "award_id": "3UM1AI148573-01S1", "title": "University of Washington Vaccine and Treatment Evaluation Unit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 7539, "first_name": "Marina", "last_name": "Lee", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-03-12", "end_date": "2022-11-30", "award_amount": 9616028, "principal_investigator": { "id": 11527, "first_name": "Helen Ying-hui", "last_name": "Chu", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23371, "first_name": "Anna", "last_name": "Wald", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "The proposed University of Washington (UW) Vaccine and Treatment Evaluation Unit (VTEU) will be led by highly experienced investigators in domestic and international clinical trials, and supported by a Steering Committee that includes leading experts in the areas of focus of this application, including respiratory infections, sexually transmitted infections, malaria challenge studies, enteric infections and other neglected tropical diseases. The co-Principal Investigators have conducted >30 clinical trials, most under IND; these include trials sponsored by NIAID, including VTEU contracts, HPTN and STI CTG, industry sponsors, and investigator-held IND. The proposed VTEU Research Clinic at Harborview Medical Center has been conducting clinical trials for several decades, and the recruitment, enrollment, and retention practices and policies have been well established. Our strong record in obtaining research funding has resulted in the UW School of Medicine providing ample space that has been specifically designed to accommodate clinical trials conducted in the area of Infectious Diseases. The UW VTEU will leverage the extraordinary breadth and depth of expertise, facilities, resources, populations, and geographic reach of the UW and our collaborating institutions. Locally, these include Seattle Children’s and the Fred Hutchinson Cancer Research Center, in addition to several campus locations for UW Medicine. Internationally, the investigators included in the UW VTEU also lead well-established and experienced research sites with outstanding infrastructure in Kenya (UW- Kenya and the Kenya Medical Research Institute), South Africa (University of Witwatersrand), and Peru (Asociación Civil Selva Amazónica). Both domestic and international investigators have vast experience in the conduct of clinical trials of vaccines and other therapeutics under IND, with many sponsored by NIAID. This consortium has demonstrated capacity to recruit and retain the populations targeted by the VTEUs, including healthy volunteers, pregnant women, children, persons with or at risk for sexually transmitted infections, and participants in human challenge studies. The Specific Aims of the UW VTEU are: 1. Recruit a wide range of participants in clinical trials approved by the Leadership Group; 2. Implement clinical trials in compliance with Good Clinical Practice Guidelines and other regulatory guidance; 3. Ensure participant safety and monitor trials for adverse events; 4. Support the Leadership Group in the development of clinical protocols, providing unique clinical and research laboratory capabilities, performing data analysis, and reporting the results of clinical trials; 5. Provide outstanding training opportunities and mentorship to early stage investigators who desire to gain experience in conducting clinical trials.", "keywords": [ "Address", "Adult", "Adverse event", "Africa South of the Sahara", "Area", "Biological Assay", "Cellular Immunology", "Child", "Childhood", "Clinic", "Clinical Investigator", "Clinical Practice Guideline", "Clinical Protocols", "Clinical Research", "Clinical Trials", "Committee Members", "Communicable Diseases", "Conduct Clinical Trials", "Contracts", "Country", "Cytomegalovirus", "Data Analyses", "Emerging Communicable Diseases", "Enrollment", "Ensure", "Evaluation", "Fred Hutchinson Cancer Research Center", "Funding", "Geography", "Good Clinical Practice", "HIV Vaccine Trials Network", "Hepatitis", "Human", "Individual", "Industry", "Influenza", "Influenza A Virus H1N1 Subtype", "Influenza A virus", "Infrastructure", "Institution", "International", "Kenya", "Knowledge", "Laboratories", "Laboratory Research", "Lead", "Leadership", "Location", "Malaria", "Medical Research", "Medical center", "Medicine", "Mentorship", "Mission", "Molecular Virology", "Monitor", "National Institute of Allergy and Infectious Disease", "Participant", "Peripheral Blood Mononuclear Cell", "Persons", "Peru", "Pharmaceutical Preparations", "Phase", "Policies", "Population", "Pregnant Women", "Principal Investigator", "Reporting", "Research", "Research Institute", "Research Personnel", "Resources", "Respiratory Tract Infections", "Ribosomal RNA", "Risk", "Running", "Safety", "Sexually Transmitted Diseases", "Simplexvirus", "Site", "South Africa", "Target Populations", "Testing", "Therapeutic", "United States National Institutes of Health", "Universities", "Vaccine Clinical Trial", "Vaccines", "Washington", "Women&apos", "s Health", "Work", "ZIKA", "clinical development", "clinical research site", "cost", "design", "enteric infection", "experience", "global health", "healthy volunteer", "industry partner", "malaria infection", "medical schools", "neglected tropical diseases", "novel", "novel strategies", "novel therapeutics", "novel vaccines", "pandemic disease", "participant safety", "programs", "recruit", "skills", "training opportunity", "vaccine development", "vaccine trial" ], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1424, "count": 14236 } } }